Clinical Trial Update: A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor [Phase 1]

View source ↗

Summary

Phase 1 study assessing the disposition (distribution and clearance) of radiolabeled AVE8062 given as a 30-minute IV infusion in patients with advanced solid tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AVE8062

Snippet

Sponsor: Sanofi | Conditions: Neoplasms, Malignant | Phase 1 | Status: COMPLETED